Optimal vitamin D status and serum parathyroid hormone concentrations in African American women - PubMed (original) (raw)
Randomized Controlled Trial
Optimal vitamin D status and serum parathyroid hormone concentrations in African American women
John F Aloia et al. Am J Clin Nutr. 2006 Sep.
Abstract
Background: Optimal vitamin D status for the prevention of osteoporosis has been inferred from examinations of the serum 25-hydroxyvitamin D [25(OH)D] concentration below which there is an increase in serum parathyroid hormone (PTH).
Objective: The objectives of the study were to ascertain whether a threshold for serum 25(OH)D exists below which serum PTH increases and whether persons with 25(OH)D above this threshold have lower rates of bone loss than do persons with 25(OH)D below the threshold.
Design: The relation of serum 25(OH)D to serum PTH was analyzed in 208 African American women studied longitudinally for 3 y. These healthy women in midlife were randomly assigned to receive placebo or 800 IU vitamin D3/d; after 2 y, the vitamin D3 supplementation was increased to 2000 IU/d. Both groups received calcium supplements to ensure an adequate calcium intake. A systematic literature review found a wide range of threshold values in part due to varied calcium intake.
Results: A Loess plot suggested a breakpoint between 40 and 50 nmol/L for serum 25(OH)D. A line-line model was fitted to the data, and it showed a spline knot at 44 nmol/L. A heuristic approach verified that PTH does not decline as rapidly when the serum concentration of 25(OH)D is >40 nmol/L as when it is <40 nmol/L. We found no significant difference in rates of bone loss between persons with 25(OH)D concentrations above and below 40 nmol/L.
Conclusion: Although a threshold for 25(OH)D can be identified, we suggest that it should not be used to recommend optimal vitamin D status.
Figures
FIGURE 1
Loess plot (solid line) and 95% CI of the Loess plot (dotted lines) of parathyroid hormone as a function of 25-hydroxyvitamin D. n = 124. The linear regression line (- - -) is outside the 95% CI for 25-hydroxyvitamin D concentrations <30 or >110 nmol/L.
Similar articles
- Dose response to vitamin D supplementation in postmenopausal women: a randomized trial.
Gallagher JC, Sai A, Templin T 2nd, Smith L. Gallagher JC, et al. Ann Intern Med. 2012 Mar 20;156(6):425-37. doi: 10.7326/0003-4819-156-6-201203200-00005. Ann Intern Med. 2012. PMID: 22431675 Clinical Trial. - Vitamin D status in a rural postmenopausal female population.
Lappe JM, Davies KM, Travers-Gustafson D, Heaney RP. Lappe JM, et al. J Am Coll Nutr. 2006 Oct;25(5):395-402. doi: 10.1080/07315724.2006.10719551. J Am Coll Nutr. 2006. PMID: 17031008 - Vitamin D status: effects on parathyroid hormone and 1, 25-dihydroxyvitamin D in postmenopausal women.
Need AG, Horowitz M, Morris HA, Nordin BC. Need AG, et al. Am J Clin Nutr. 2000 Jun;71(6):1577-81. doi: 10.1093/ajcn/71.6.1577. Am J Clin Nutr. 2000. PMID: 10837301 - Effectiveness and safety of vitamin D in relation to bone health.
Cranney A, Horsley T, O'Donnell S, Weiler H, Puil L, Ooi D, Atkinson S, Ward L, Moher D, Hanley D, Fang M, Yazdi F, Garritty C, Sampson M, Barrowman N, Tsertsvadze A, Mamaladze V. Cranney A, et al. Evid Rep Technol Assess (Full Rep). 2007 Aug;(158):1-235. Evid Rep Technol Assess (Full Rep). 2007. PMID: 18088161 Free PMC article. Review. - Vitamin D supplementation in elderly or postmenopausal women: a 2013 update of the 2008 recommendations from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO).
Rizzoli R, Boonen S, Brandi ML, Bruyère O, Cooper C, Kanis JA, Kaufman JM, Ringe JD, Weryha G, Reginster JY. Rizzoli R, et al. Curr Med Res Opin. 2013 Apr;29(4):305-13. doi: 10.1185/03007995.2013.766162. Epub 2013 Feb 7. Curr Med Res Opin. 2013. PMID: 23320612
Cited by
- The association of parathyroid hormone with serum 25-hydroxyvitamin during pregnancy.
Kazemian E, Madreseh E, Azizi F, Ashrafivand S, Gargari SS, Mansournia MA, Wagner CL, Amouzegar A. Kazemian E, et al. J Nutr Sci. 2023 Jan 6;12:e1. doi: 10.1017/jns.2022.110. eCollection 2023. J Nutr Sci. 2023. PMID: 36721726 Free PMC article. - Optimal Serum 25(OH)D Level and Vitamin D Intake in Young Korean Women.
Shin HR, Park HJ, Ly SY. Shin HR, et al. Nutrients. 2022 Nov 16;14(22):4845. doi: 10.3390/nu14224845. Nutrients. 2022. PMID: 36432534 Free PMC article. - Plasma parathyroid hormone response to vitamin D3 supplementation among women of reproductive age: A randomized double-blind placebo-control trial.
Zan MCH, Ying MLE, Cheong LS, Lin KG. Zan MCH, et al. PLoS One. 2022 Nov 10;17(11):e0276506. doi: 10.1371/journal.pone.0276506. eCollection 2022. PLoS One. 2022. PMID: 36356037 Free PMC article. Clinical Trial. - Applying Machine Learning to Determine 25(OH)D Threshold Levels Using Data from the AMATERASU Vitamin D Supplementation Trial in Patients with Digestive Tract Cancer.
Otani K, Kanno K, Akutsu T, Ohdaira H, Suzuki Y, Urashima M. Otani K, et al. Nutrients. 2022 Apr 19;14(9):1689. doi: 10.3390/nu14091689. Nutrients. 2022. PMID: 35565657 Free PMC article. - Threshold for Relationship between Vitamin D and Parathyroid Hormone in Chinese Women of Childbearing Age.
Hu Y, Li S, Wang J, Zheng D, Zhang H, Yu W, Zhu L, Liu Z, Yang X, Yang L. Hu Y, et al. Int J Environ Res Public Health. 2021 Dec 10;18(24):13060. doi: 10.3390/ijerph182413060. Int J Environ Res Public Health. 2021. PMID: 34948669 Free PMC article.
References
- Heaney RP, Weaver CM. Calcium and vitamin D. Endocrinol Metab Clin North Am. 2003;32:181–94. - PubMed
- NIH Consensus Conference. Optimal calcium intake. NIH Consensus Development Panel on Optimal Calcium Intake. JAMA. 1994;272:1942–8. - PubMed
- Osteoporosis prevention, diagnosis, and therapy. NIH Consens Statement. 2000;17:1–45. - PubMed
- Standing Committee on the Scientific Evaluation of Dietary Reference Intakes Food and Nutrition Board Institute of Medicine. Washington, DC: National Academy Press; 1997. Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 AG015325-04/AG/NIA NIH HHS/United States
- R01 AG015325-04S1/AG/NIA NIH HHS/United States
- AG15325/AG/NIA NIH HHS/United States
- R01 AG015325/AG/NIA NIH HHS/United States
- R01 AG015325-05/AG/NIA NIH HHS/United States
- R01 AG015325-02/AG/NIA NIH HHS/United States
- R01 AG015325-03/AG/NIA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical